Previous Close | 7.00 |
Open | 7.00 |
Bid | 4.00 x 900 |
Ask | 6.65 x 1100 |
Day's Range | 6.43 - 7.10 |
52 Week Range | 3.81 - 27.92 |
Volume | |
Avg. Volume | 328,265 |
Market Cap | 388.321M |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.90 |
Earnings Date | Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.90 |
Subscribe to Yahoo Finance Plus to view Fair Value for IGMS
In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […]
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development in hematologic oncology indications halted – – Cash runway expected to extend into second quarter 2026 – – Reduction in workforce of approximately 22 percent – MOUNTAIN VIEW, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnol
Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The general meeting was held at Helio GT30 on Grev Turegatan 30 in Stockholm. For more detailed information on the content of the resolution, please see the complete notice of the extraordinary general meeting that is available on the Company's website, www.medivir.com. Minutes from the extraordinary general meeting will be provided on the said